

February 14, 2025

BSE Limited Code: 532321

P J Towers, Dalal Street, <u>Mumbai-400001</u>

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: <u>Press Release</u>

Dear Sir / Madam,

Please find enclosed a copy of press release dated February 14, 2025, titled "Stock Exchange intimation on closure of USFDA inspection at Zydus' topical plant".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,
For, ZYDUS LIFESCIENCES LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Code: Zyduslife



## Stock Exchange intimation on closure of USFDA inspection at Zydus' topical plant

Ahmedabad, India, 14 February, 2025

We wish to inform that the USFDA conducted a routine surveillance inspection at the group's Topical Manufacturing site situated at Changodar in Ahmedabad. The inspection was conducted from February 10th to 14th, 2025.

The inspection concluded with NIL observations.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

\*\*\*



For further information please contact: The Corporate Communications Department

## Zydus Lifesciences Limited

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone: +91-79-71800000, +91-79-48040000 | website: www.zyduslife.com CIN: L24230GJ1995PLC025878